



(86) Date de dépôt PCT/PCT Filing Date: 2010/04/06
(87) Date publication PCT/PCT Publication Date: 2010/10/14
(85) Entrée phase nationale/National Entry: 2011/10/07
(86) N° demande PCT/PCT Application No.: US 2010/030039
(87) N° publication PCT/PCT Publication No.: 2010/117980
(30) Priorité/Priority: 2009/04/10 (US61/168,411)

(51) Cl.Int./Int.Cl. *C07K 16/18* (2006.01)
(71) Demandeur/Applicant:
ELI LILLY AND COMPANY, US
(72) Inventeurs/Inventors:
CHEDID, MARCIO, US;
DARLING, RYAN JAMES, US;
GALVIN, RACHELLE JEANETTE, US;
SWANSON, BARBARA ANNE, US
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : ANTICORPS ANTI-DKK-1
(54) Title: DKK-1 ANTIBODIES

(57) **Abrégé/Abstract:**

The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 October 2010 (14.10.2010)(10) International Publication Number
WO 2010/117980 A1(51) International Patent Classification:
C07K 16/18 (2006.01)(21) International Application Number:
PCT/US2010/030039(22) International Filing Date:
6 April 2010 (06.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/168,411 10 April 2009 (10.04.2009) US(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEDID, Marcio** [BR/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **DARLING, Ryan, James** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **GALVIN, Rachelle, Jeanette** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **SWANSON, Barbara, Anne** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US).(74) Agents: **CASTETTER, Andrea, M.** et al.; Eli Lilly and Company, Patent Division, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DKK-1 ANTIBODIES

(57) Abstract: The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.



WO 2010/117980 A1

-1-

DKK-1 Antibodies

The present invention relates to human engineered antibodies against DKK-1 and their use in treating diseases in which pathogenesis is mediated by DKK-1.

Dickkopf-1 (Dkk-1) is a member of the dickkopf family of proteins that have been
5 shown to be negative regulators of the canonical Wnt-signaling pathway. The pathway plays a central role in bone development and formation. Dkk-1 inhibits Wnt signaling through its interaction with the Wnt co-receptor LRP5 or LRP6 and the kremen proteins. Dkk-1 prevents members of the Wnt pathway from interacting with either LRP5 or LRP6, thus preventing Wnt-mediated signal transduction. DKK1 has also been shown to be
10 involved in bone metastasizing cancers, including multiple myeloma, breast carcinoma, renal carcinoma and non-small cell lung cancer.

Antibodies that bind Dkk-1 have been described (for example, see WO2006015373), however, there is still a need for therapeutic human engineered DKK-1 antibodies that will inhibit the interaction of Dkk-1 with LRP5 and LRP6. In addition, in
15 view of the involvement of Dkk-1 in the regulation of bone formation, there is a need for therapeutic human engineered anti-Dkk-1 antibodies for use in bone healing. In addition, given the involvement of Dkk-1 in cancers, there is a need for human engineered anti-Dkk-1 antibodies for treating cancers, including multiple myeloma, breast and non-small cell lung cancers.

20 The antibodies of the present invention are therapeutically useful DKK-1 antagonists possessing a number of desirable properties. The present human engineered antibodies exhibit high affinity (Kd) to human DKK-1, cynomolgus DKK-1, rat DKK-1, mouse DKK-1, and rabbit DKK-1. Antibodies of the present invention block DKK-1-mediated inhibition of alkaline phosphatase, a marker of osteoblast activity. Furthermore,
25 antibodies of the present invention exhibit an increase in bone mass density at both anterior and posterior cortices in a cortical defect in vivo model and demonstrate significant growth inhibition of non-small cell lung xenografts in vivo.

The present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof that has a Kd at 37°C of less than 5.0×10^{-11} M for human
30 DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32).

-2-

The present invention provides a human engineered DKK-1 antibody or a binding fragment thereof wherein LCDR1 has the amino sequence of SEQ ID NO:5, LCDR2 has the amino sequence of SEQ ID NO:47, LCDR3 has the amino sequence of SEQ ID NO:49, HCDR1 has the amino sequence of SEQ ID NO:1, HCDR2 has the amino
5 sequence of SEQ ID NO:2, and HCDR3 has the amino sequence of SEQ ID NO:44.

The present invention also provides a pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient.

The present invention provides a method of healing bone comprising
10 administering a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention. The present invention also provides a method of treating cancer comprising administering a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention, wherein the cancer is selected from the group consisting of multiple myeloma, breast cancer and non-small cell lung cancer.

15 The present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof as described herein, wherein the antibody has a K_d of less than 1.5×10^{-11} M for human DKK-1 (SEQ ID NO: 29). More preferably, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d of less than 1.0×10^{-11} M for human DKK-1 (SEQ
20 ID NO: 29). Further preferred, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d of less than 5.0×10^{-12} M for human DKK-1 (SEQ ID NO: 29). More preferably, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d between 0.5×10^{-12} M and 1.5×10^{-11} M for
25 human DKK-1 (SEQ ID NO: 29). Further preferred, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d between 1.0×10^{-12} M and 1.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29). The K_d values are established by a binding equilibrium at 37°C as described in Example 2.

30 The present invention also provides a human engineered DKK-1 antibody or antigen-binding fragment thereof as described herein, wherein the antibody has a K_d of less than 5.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ

-3-

ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). More preferably, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d of less than 3.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). Further preferred, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d of less than 2.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), rat Dkk-1 (SEQ ID NO: 31), and mouse DKK-1 (SEQ ID NO: 33). More preferably, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d between 1.0×10^{-11} M and 5.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). Further preferred, the present invention provides human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the antibody has a K_d between 1.5×10^{-11} M and 3.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), rat Dkk-1 (SEQ ID NO: 31), and mouse DKK-1 (SEQ ID NO: 33). The K_d values are established by a binding equilibrium at 37°C as described in Example 2.

More preferably, the present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12 and wherein the human engineered DKK-1 antibody or antigen-binding fragment thereof has a K_d of less than 3.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). Further preferred, the present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12 and wherein the human engineered DKK-1 antibody or antigen-binding fragment thereof has a K_d of less than 2.5×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). More preferably, the present invention provides a human engineered DKK-1

-4-

antibody or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12 and wherein the human engineered DKK-1 antibody or antigen-binding fragment thereof has a K_d of less than 2.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). Further preferred, the present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12 and wherein the human engineered DKK-1 antibody or antigen-binding fragment thereof has a K_d between 0.5×10^{-12} M and 3.0×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). More preferably, the present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12 and wherein the human engineered DKK-1 antibody or antigen-binding fragment thereof has a K_d between 1.0×10^{-12} M and 2.5×10^{-11} M for human DKK-1 (SEQ ID NO: 29), cynomolgus DKK-1 (SEQ ID NO: 30), rat Dkk-1 (SEQ ID NO: 31), mouse DKK-1 (SEQ ID NO: 33), and rabbit DKK-1 (SEQ ID NO: 32). The K_d values are established by a binding equilibrium at 37°C as described in Example 2.

The present invention provides a human engineered DKK-1 antibody or a binding fragment thereof, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO:5, HCDR1 has the amino sequence of SEQ ID NO:1, and HCDR2 has the amino sequence of SEQ ID NO:2.

The present invention provides a human engineered DKK-1 antibody or a binding fragment thereof wherein LCDR1 has the amino sequence of SEQ ID NO:46, LCDR2 has the amino sequence of SEQ ID NO:48, LCDR3 has the amino sequence of SEQ ID NO:50, HCDR1 has the amino sequence of SEQ ID NO:1, HCDR2 has the amino

-5-

sequence of SEQ ID NO:43, and HCDR3 has the amino sequence of SEQ ID NO:45. The present invention preferably provides a human engineered DKK-1 antibody or a binding fragment thereof wherein LCDR1 has the amino sequence of SEQ ID NO:5, LCDR2 has the amino sequence of SEQ ID NO:47, LCDR3 has the amino sequence of
5 SEQ ID NO:49, HCDR1 has the amino sequence of SEQ ID NO:1, HCDR2 has the amino sequence of SEQ ID NO:2, and HCDR3 has the amino sequence of SEQ ID NO:44.

The present invention provides a human engineered DKK-1 antibody or a binding fragment thereof wherein LCDR1 has the amino sequence of SEQ ID NO:5, LCDR2 has
10 an amino sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:10, LCDR3 has an amino sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:9, HCDR1 has the amino sequence of SEQ ID NO:1, HCDR2 has the amino sequence of SEQ ID NO:2, and HCDR3 has an amino sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

15 The present invention preferably provides a human engineered DKK-1 antibody or antigen-binding fragment thereof wherein LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 and HCDR3 have amino acid sequences selected from the group consisting of:

(i) LCDR1 is SEQ ID NO: 5, LCDR2 is SEQ ID NO: 6, LCDR3 is SEQ ID NO: 7, HCDR1 is SEQ ID NO: 1, HCDR2 is SEQ ID NO: 2, and
20 HCDR3 is SEQ ID NO: 3,

(ii) LCDR1 is SEQ ID NO: 5, LCDR2 is SEQ ID NO: 8, LCDR3 is SEQ ID NO: 7, HCDR1 is SEQ ID NO: 1, HCDR2 is SEQ ID NO: 2, and
HCDR3 is SEQ ID NO: 4,

(iii) LCDR1 is SEQ ID NO: 5, LCDR2 is SEQ ID NO: 6, LCDR3 is SEQ ID NO: 9, HCDR1 is SEQ ID NO: 1, HCDR2 is SEQ ID NO: 2, and
25 HCDR3 is SEQ ID NO: 3,

(iv) LCDR1 is SEQ ID NO: 5, LCDR2 is SEQ ID NO: 10, LCDR3 is SEQ ID NO: 9, HCDR1 is SEQ ID NO: 1, HCDR2 is SEQ ID NO: 2, and
HCDR3 is SEQ ID NO: 3

30 The present invention provides a human engineered DKK-1 antibody or antigen-binding fragment thereof wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 52 and the HCVR comprises the amino acid sequence of SEQ ID NO: 51.

-6-

The present invention preferably provides a human engineered DKK-1 antibody or antigen-binding fragment thereof wherein the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.

5 The present invention preferably provides a human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:11 and SEQ ID NO:12.

 The present invention preferably provides a human engineered DKK-1 antibody or antigen-binding fragment thereof, wherein the LCVR and HCVR comprise amino acid
10 sequences selected from the group consisting of:

- (i) a LCVR comprising the amino acid sequence of SEQ ID NO:13 and a HCVR comprising the amino acid sequence of SEQ ID NO:11;
- (ii) a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12;
- 15 (iii) a LCVR comprising the amino acid sequence of SEQ ID NO:15 and a HCVR comprising the amino acid sequence of SEQ ID NO:11;
- (iv) a LCVR comprising the amino acid sequence of SEQ ID NO:16 and a HCVR comprising the amino acid sequence of SEQ ID NO:11.

 The present invention preferably provides a human engineered DKK-1 antibody
20 or antigen-binding fragment thereof comprising a LCVR comprising the amino acid sequence of SEQ ID NO:14 and a HCVR comprising the amino acid sequence of SEQ ID NO:12.

 The present invention preferably provides a human engineered DKK-1 antibody wherein the human engineered DKK-1 antibody comprises a light chain wherein the light
25 chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.

 The present invention preferably provides a human engineered DKK-1 antibody, wherein the human engineered DKK-1 antibody comprises a heavy chain wherein the heavy chain comprises an amino acid sequence selected from the group consisting of
30 SEQ ID NO:17 and SEQ ID NO:18.

-7-

More preferably, the present invention provides a human engineered DKK-1 antibody, wherein the human engineered DKK-1 antibody comprises a heavy chain and a light chain amino acid sequence selected from the group consisting of

- 5 (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:17 and light chain comprising the amino acid sequence of SEQ ID NO:19,
- (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO:18 and a light chain comprising the amino acid sequence of SEQ ID NO:20,
- 10 (iii) a heavy chain comprising the amino acid sequence of SEQ ID NO:17 and a light chain comprising the amino acid sequence of SEQ ID NO:21, and
- (iv) a heavy chain comprising the amino acid sequence of SEQ ID NO:17 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

15 The present invention preferably provides a human engineered DKK-1 antibody comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO: 19, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO:17.

20 The present invention preferably provides a human engineered DKK-1 antibody comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO: 21, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO:17.

25 The present invention preferably provides a human engineered DKK-1 antibody comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO:22, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO:17.

30 The present invention preferably provides a human engineered DKK-1 antibody comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO: 20, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO:18.

The present invention also provides an antibody or antigen-binding fragment thereof, which competes with the human engineered DKK-1 antibody or antigen-binding

-8-

fragment thereof of the present invention for binding to human DKK-1 (SEQ ID NO: 29) as determined via an antibody competition assay.

The present invention also provides a pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient.

Furthermore, the present invention provides a pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof of the present invention together with a pharmaceutically acceptable carrier, diluent, or excipient and optionally other therapeutic ingredients.

In a further aspect, the present invention provides a method of healing bone comprising administering a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention.

In a further aspect, the present invention provides a method of treating cancer comprising administering a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention, wherein the cancer is preferably selected from the group consisting of multiple myeloma, breast cancer and non-small cell lung cancer.

Furthermore, the present invention provides a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention for use in therapy. Preferably, the present invention provides a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention for use in the treatment for healing bone or in the treatment of cancer, wherein the cancer is preferably selected from the group consisting of multiple myeloma, breast cancer and non-small cell lung cancer.

Furthermore, the present invention also provides for the use of a human engineered DKK-1 antibody or antigen binding fragment thereof of the present invention in the manufacture of a medicament for therapy, healing bone or to treat cancer, wherein the cancer is preferably selected from the group consisting of multiple myeloma, breast cancer and non-small cell lung cancer.

Definitions

A full-length antibody as it exists naturally is an immunoglobulin molecule comprising 2 heavy (H) chains and 2 light (L) chains interconnected by disulfide bonds. The amino terminal portion of each chain includes a variable region of about 100-110 amino acids primarily responsible for antigen recognition via the complementarity

-9-

determining regions (CDRs) contained therein. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

The CDRs are interspersed with regions that are more conserved, termed framework regions ("FR"). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) is composed of 3 CDRs and 4 FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The 3 CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3" and the 3 CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3." The CDRs contain most of the residues which form specific interactions with the antigen. The numbering and positioning of CDR amino acid residues within the LCVR and HCVR regions is in accordance with the well-known Kabat numbering convention.

Light chains are classified as kappa or lambda, and are characterized by a particular constant region as known in the art. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the isotype of an antibody as IgG, IgM, IgA, IgD, or IgE, respectively. IgG antibodies can be further divided into subclasses, e.g., IgG1, IgG2, IgG3, IgG4. Each heavy chain type is characterized by a particular constant region with a sequence well known in the art.

As used herein, the term "monoclonal antibody" (Mab) refers to an antibody that is derived from a single copy or clone including, for example, any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Mabs of the present invention preferably exist in a homogeneous or substantially homogeneous population. Complete Mabs contain 2 heavy chains and 2 light chains. "Antigen-binding fragments" of such monoclonal antibodies include, for example, Fab fragments, Fab' fragments, F(ab')₂ fragments, and single chain Fv fragments. Monoclonal antibodies and antigen-binding fragments thereof of the present invention can be produced, for example, by recombinant technologies, phage display technologies, synthetic technologies, e.g., CDR-grafting, or combinations of such technologies, or other technologies known in the art. For example, mice can be immunized with human DKK-1 or fragments thereof, the resulting antibodies can be recovered and purified, and determination of whether they possess binding and functional properties similar to or the same as the antibody compounds disclosed herein can be assessed by the methods disclosed in Examples

-10-

below. Antigen-binding fragments can also be prepared by conventional methods. Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art and can be found, for example, in Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, chapters 5-8 and 15, ISBN 0-87969-314-2.

The phrase “chimeric antibody” refers to an antibody containing domains from different species (generally 2 species). Antibody V is a chimeric antibody wherein the light chain and heavy chain variable domains contain residues from a murine antibody, whereas the constant region light chain domain contains residues comprising a rat kappa light chain and the constant region heavy chain domains contains residues comprising a rat IgG1 antibody. Antibody V is a murine/rat chimera and is used in studies to reduce the likelihood of immune response in long-term pre-clinical models.

The phrase “human engineered antibodies” refers to monoclonal antibodies that have binding and functional properties according to the invention, and that have framework regions that are substantially human or fully human surrounding CDRs derived from a non-human antibody. “Antigen-binding fragments” of such human engineered antibodies include, for example, Fab fragments, Fab’ fragments, F(ab’)₂ fragments, and single chain Fv fragments. “Framework region” or “framework sequence” refers to any one of framework regions 1 to 4. Human engineered antibodies and antigen-binding fragments thereof encompassed by the present invention include molecules wherein any one or more of framework regions 1 to 4 is substantially or fully human, i.e., wherein any of the possible combinations of individual substantially or fully human framework regions 1 to 4, is present. For example, this includes molecules in which framework region 1 and framework region 2, framework region 1 and framework region 3, framework region 1, 2, and 3, etc., are substantially or fully human. Substantially human frameworks are those that have at least about 80% sequence identity to a known human germline framework sequence. Preferably, the substantially human frameworks have at least about 85%, about 90%, about 95%, or about 99% sequence identity to a known human germline framework sequence.

Fully human frameworks are those that are identical to a known human germline framework sequence. Human framework germline sequences can be obtained from ImMunoGeneTics (IMGT) via their website <http://imgt.cines.fr>, or from *The*

-11-

Immunoglobulin FactsBook by Marie-Paule Lefranc and Gerard Lefranc, Academic Press, 2001, ISBN 012441351. For example, germline light chain frameworks can be selected from the group consisting of: A11, A17, A18, A19, A20, A27, A30, LI, L1I, L12, L2, L5, L15, L6, L8, O12, O2, and O8, and germline heavy chain framework regions can
5 be selected from the group consisting of: VH2-5, VH2-26, VH2-70, VH3-20, VH3-72, VHI-46, VH3-9, VH3-66, VH3-74, VH4-31, VHI-18, VHI-69, VI-13-7, VH3-11, VH3-15, VH3-21, VH3-23, VH3-30, VH3-48, VH4-39, VH4-59, and VH5-5I.

Human engineered antibodies in addition to those disclosed herein exhibiting similar functional properties according to the present invention can be generated using
10 several different methods. The specific antibody compounds disclosed herein can be used as templates or parent antibody compounds to prepare additional antibody compounds. In one approach, the parent antibody compound CDRs are grafted into a human framework that has a high sequence identity with the parent antibody compound framework. The sequence identity of the new framework will generally be at least about 80%, at least
15 about 85%, at least about 90%, at least about 95%, or at least about 99% identical to the sequence of the corresponding framework in the parent antibody compound. This grafting may result in a reduction in binding affinity compared to that of the parent antibody. If this is the case, the framework can be back-mutated to the parent framework at certain positions based on specific criteria disclosed by Queen et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:2869. Additional references describing methods useful in humanizing
20 mouse antibodies include U.S. Patent Nos. 4,816,397; 5,225,539, and 5,693,761; computer programs ABMOD and ENCAD as described in Levitt (1983) *J. Mol. Biol.* 168:595-620; and the method of Winter and co-workers (Jones et al. (1986) *Nature* 321:522-525; Riechmann et al. (1988) *Nature* 332:323-327; and Verhoeyen et al. (1988)
25 *Science* 239:1534-1536.

The identification of residues to consider for back-mutation can be carried out as follows:

When an amino acid falls under the following category, the framework amino acid of the human germ-line sequence that is being used (the “acceptor framework”) is
30 replaced by a framework amino acid from a framework of the parent antibody compound (the “donor framework”):

-12-

(a) the amino acid in the human framework region of the acceptor framework is unusual for human frameworks at that position, whereas the corresponding amino acid in the donor immunoglobulin is typical for human frameworks at that position;

5 (b) the position of the amino acid is immediately adjacent to one of the CDRs; or

(c) any side chain atom of a framework amino acid is within about 5-6 angstroms (center-to-center) of any atom of a CDR amino acid in a three dimensional immunoglobulin model.

10 When each of the amino acids in the human framework region of the acceptor framework and a corresponding amino acid in the donor framework is generally unusual for human frameworks at that position, such amino acid can be replaced by an amino acid typical for human frameworks at that position. This back-mutation criterion enables one to recover the activity of the parent antibody compound.

15 Another approach to generating human engineered antibodies exhibiting similar functional properties to the antibody compounds disclosed herein involves randomly mutating amino acids within the grafted CDRs without changing the framework, and screening the resultant molecules for binding affinity and other functional properties that are as good as or better than those of the parent antibody compounds. Single mutations
20 can also be introduced at each amino acid position within each CDR, followed by assessing the effects of such mutations on binding affinity and other functional properties. Single mutations producing improved properties can be combined to assess their effects in combination with one another.

Further, a combination of both of the foregoing approaches is possible. After
25 CDR grafting, one can back-mutate specific framework regions in addition to introducing amino acid changes in the CDRs. This methodology is described in Wu et al. (1999) *J. Mol. Biol.* 294:151-162.

Applying the teachings of the present invention, a person skilled in the art can use common techniques, e.g., site-directed mutagenesis, to substitute amino acids within the
30 presently disclosed CDR and framework sequences and thereby generate further variable region amino acid sequences derived from the present sequences. All alternative naturally occurring amino acids can be introduced at a specific substitution site. The

-13-

methods disclosed herein can then be used to screen these additional variable region amino acid sequences to identify sequences having the indicated *in vivo* functions. In this way, further sequences suitable for preparing human engineered antibodies and antigen-binding portions thereof in accordance with the present invention can be identified.

- 5 Preferably, amino acid substitution within the frameworks is restricted to one, two, or three positions within any one or more of the 4 light chain and/or heavy chain framework regions disclosed herein. Preferably, amino acid substitution within the CDRs is restricted to one, two, or three positions within any one or more of the 3 light chain and/or heavy chain CDRs. Combinations of the various changes within these framework regions and CDRs described above are also possible. Most preferably, these techniques are used to generate further variable region amino acid sequences using the variable heavy and light chain amino acid sequences describes in SEQ ID NO:12 and SEQ ID NO:14 respectively.

- Human engineered antibodies or antigen-binding fragments thereof that
- 15 “compete” with the molecules disclosed herein are those that bind human DKK-1 (SEQ ID NO:29) at site(s) that are identical to, or overlapping with, the site(s) at which the present molecules bind. Competing human engineered antibodies or antigen-binding fragments thereof can be identified, for example, via an antibody competition assay. For example, a sample of purified or partially purified human DKK-1 (SEQ ID NO:29) is
- 20 bound to a solid support. An antibody disclosed herein and a test monoclonal antibody or antigen-binding fragment, with either the test or antibody of the present invention labeled, are then added. If the labeled antibody and the unlabeled antibody bind to separate and discrete sites on DKK-1, the labeled antibody will bind to the same level whether or not the suspected competing antibody is present. However, if the sites of interaction are
- 25 identical or overlapping, the unlabeled antibody will compete, and the amount of labeled antibody bound to the antigen will be lowered. If the unlabeled antibody is present in excess, no labeled antibody will bind. For purposes of the present invention, competing human engineered antibodies or antigen-binding fragments thereof are those that decrease the binding of the present antibodies to DKK-1 by about 50%, about 60%, about 70%,
- 30 about 80%, about 85%, about 90%, about 95%, or about 99%. Details of procedures for carrying out such competition assays are well known in the art and can be found, for example, in Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring

-14-

Harbor Laboratory Press, Cold Spring Harbor, New York, pages 567-569, ISBN 0-87969-314-2. Such assays can be made quantitative by using purified antibodies. A standard curve is established by titrating one antibody against a labeled version of itself. The capacity of an unlabeled competing monoclonal antibody or antigen-binding fragment thereof to inhibit the binding of the labeled molecule to the plate is titrated. The results are plotted, and the concentrations necessary to achieve the desired degree of binding inhibition are compared. Whether monoclonal antibodies or antigen-binding fragments thereof that compete with human engineered antibodies or antigen-binding fragments thereof of the present invention in such competition assays possess the same or similar functional properties of the present human engineered antibodies can be determined via the methods disclosed in Examples herein.

The term “inhibit” means the ability to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, eliminate, stop, reduce, or reverse the biological effects of DKK-1.

The term “treating” (or “treat” or “treatment”) refers to processes involving a slowing, interrupting, arresting, controlling, stopping, reducing, or reversing the progression or severity of a symptom, disorder, condition, or disease, but does not necessarily involve a total elimination of all disease-related symptoms, conditions, or disorders associated with DKK-1 activity.

The term “preventing” (or “prevent” or “prevention”) means prohibiting, restraining, or inhibiting the incidence or occurrence of a symptom, disorder, condition, or disease. Acute events and chronic conditions may be treated and prevented. In an acute event, an antibody or antigen-binding fragment thereof is administered at the onset of a symptom, disorder, condition, or disease, and is discontinued when the acute event ends. In contrast, a chronic symptom, disorder, condition, or disease is treated over a more protracted time frame.

The term “effective amount” refers to the amount or dose of an antibody compound of the present invention which, upon single or multiple dose administration to a patient, provides the desired treatment or prevention. Therapeutically effective amounts of the present antibody compounds can comprise an amount in the range of from about 0.1 mg/kg to about 20 mg/kg per single dose. A therapeutically effective amount for any individual patient can be determined by the health care provider by monitoring the effect of the antibody compounds on a biomarker.

-15-

The term “bone healing” refers to the stimulation of bone formation at sites of injury by blocking DKK-1. Examples of bone healing indications include, but are not limited to, fracture healing, implant fixation/retention, and dental implant fixation/retention.

5 The human engineered antibodies of the present invention can be used as medicaments in human medicine, administered by a variety of routes. Most preferably, such compositions are for parenteral administration. Such pharmaceutical compositions can be prepared by methods well known in the art (*See, e.g., Remington: The Science and Practice of Pharmacy*, 19th ed. (1995), A. Gennaro et al., Mack Publishing Co.) and
10 comprise a human engineered antibody as disclosed herein, and a pharmaceutically acceptable carrier, diluent, or excipient.

 The results of the following assays demonstrate that the monoclonal antibodies and antigen-binding fragments thereof, of the present invention are useful as a DKK-1 inhibitor. The antibodies of the present invention possess a number of desirable
15 properties. For example, Antibody II of the present invention has increased chemical and physical stability, and solubility. Accelerated studies are performed to assess the chemical stability of antibodies by incubating the antibodies of the present invention under different buffer conditions (pH and NaCl variation) and incubating at 4°C, 25°C, and 40°C for 4 weeks. Chemical modifications of the antibodies of the present invention
20 are detected by cation-exchange (“CEX”) chromatography to separate charge variants (eg., deamidation of asparagine to aspartic acid) and LC-MS analysis to identify specific sites of degradation. Antibody II has the least amount of degradation detected by CEX and this result is further confirmed by LC-MS data showing that all three asparagine residues in the CDRs had the least amount of deamidation compared to the other
25 antibodies described herein after 4-week incubation at 40°C in pH 8 buffer. Solubility for Antibody II is more favorable compared to Antibody I when formulated at pH 6 + 150 mM NaCl. Furthermore, Antibody II maintained solubility of >105 mg/mL when stored in 4°C, whereas solubility for Antibody I is only 48 mg/mL and precipitated under these same conditions. As used herein, “EC50” refers to the concentration of an agent which
30 produces 50% of the maximal response possible for that agent. “Kd” refers to the equilibrium dissociation constant which can be calculated by the formula: $k_{\text{off}}/k_{\text{on}} = K_d$.

-16-

Example 1-Production of Antibodies

Antibodies I, II, III, and IV can be made and purified as follows. An appropriate host cell, such as HEK 293 EBNA or CHO, is either transiently or stably transfected with an expression system for secreting antibodies using an optimal predetermined HC:LC

5 vector ratio or a single vector system encoding both HC, such as SEQ ID NO: 23, or SEQ ID NO: 24, and LC, such as SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, or SEQ ID NO: 28. Clarified media, into which the antibody has been secreted, is purified using any of many commonly-used techniques. For example, the medium may be conveniently applied to a Protein A or G Sepharose FF column that has been equilibrated with a

10 compatible buffer, such as phosphate buffered saline (pH 7.4). The column is washed to remove nonspecific binding components. The bound antibody is eluted, for example, by pH gradient (such as 0.1 M sodium phosphate buffer pH 6.8 to 0.1 M sodium citrate buffer pH 3.0). Antibody fractions are detected, such as by SDS-PAGE, and then are pooled. Further purification is optional, depending on the intended use. The antibody

15 may be concentrated and/or sterile filtered using common techniques. Soluble aggregate and multimers may be effectively removed by common techniques, including size exclusion, hydrophobic interaction, ion exchange, or hydroxyapatite chromatography. The purity of the antibody after these chromatography steps is greater than 99%. The product may be immediately frozen at -70°C or may be lyophilized. The amino acid

20 sequences for these antibodies are provided below.

SEQ ID NOs

Antibody	Heavy Chain	Light Chain	HCVR	LCVR
I	17	19	11	13
II	18	20	12	14
III	17	21	11	15
IV	17	22	11	16
V	35	34	37	36

-17-

Antibody	HCDR1	HCDR2	HCDR3	LCDR1	LCDR2	LCDR3
I	1	2	3	5	6	7
II	1	2	4	5	8	7
III	1	2	3	5	6	9
IV	1	2	3	5	10	9
V	1	38	39	40	41	42

Example 2: Affinity (Kd) measurements for DKK-1 antibodies

To establish a binding equilibrium, a constant concentration of antibody is mixed
 5 with varying concentrations of His-tagged DKK-1 (SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, or SEQ ID NO:33) (1 nM - 1 pM range) in PBS (pH 7.4) + 1 mg/mL bovine serum albumin ("BSA") or buffer alone and incubated for several days at 37°C. Two sets of binding reactions are set up, one set at low concentration of antibody (3 pM) and one set at high concentration of antibody (30 or 50 pM).

10 After establishing equilibrium, a KinExA 3000 instrument (Sapidyne Inst. Inc.) is used to probe for the fraction of 'free' (unbound) antibody. Briefly, His-tagged DKK-1 is covalently coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare) which are packed by the instrument to create a small column. The pre-equilibrated mixtures of antibody + His-tagged DKK-1 are passed over the beads to capture only free
 15 antibody. The amount of free antibody captured is proportional to the free concentration in the equilibrated samples, and is detected by injection of a fluorescently labeled secondary antibody. Data sets from low and high concentrations of antibody are fit globally using n-curve analysis in the KinExA software. This fitting returns a Kd value as well as the 95% confidence interval.

-18-

Table 1: Antibody II affinity to DKK-1 from various species

DKK-1 Species	Kd (pM)	95% Confidence Interval for Kd (pM)
Human	3.3	1.4 – 7.5
Cynomolgus	14	8.4 - 26
Rat	8.4	3.9 - 23
Murine	7.0	4.7 - 11
Rabbit	17	11 - 27

Example 3: Effect of Dkk-1 antibodies in C2C12 alkaline phosphatase assay

5 Canonical Wnt signaling is important for osteoblast differentiation and activity. Wnt-3a CM (Conditioned Media) combined with BMP-4 induces pluripotent mouse C2C12 cells to differentiate into osteoblasts with a measurable endpoint of alkaline phosphatase (“AP”), a marker of osteoblast activity. DKK-1, an inhibitor of canonical Wnt signaling, inhibits the differentiation and production of AP. Neutralizing DKK-1
10 antibodies prevent DKK-1-mediated inhibition of AP. Antibodies which block DKK-1 inhibitory activity prevent the loss of AP activity.

C2C12 cells are grown to 60% - 80% confluence in tissue culture flasks in growth medium (Dulbecco’s Modified Eagle’s Medium (“DMEM”) containing L-glutamine, 10% heat-inactivated fetal bovine serum (“FBS”), 1x antibiotic/antimycotic, 1x sodium
15 pyruvate). C2C12 cells are resuspended to a concentration of 30,000 cells/mL in growth medium and 100 μ L/well are added to a 96-well tissue culture plate and incubated overnight at 37°C, 95% humidity, 5% CO₂. Growth medium is replaced with 50 μ L assay medium (DMEM containing L-glutamine, 5% heat-inactivated FBS, 1x
antibiotic/antimycotic, 1x sodium pyruvate). To stimulate differentiation (and thus
20 induce AP production), 100 μ L assay medium plus 1.5x Wnt-3a CM + BMP-4 (R & D Systems catalogue #314-BP) are added. This yields a final concentration of 1x Wnt-3a CM and 25 ng/mL BMP-4. Negative controls contain only L-cell CM (no Wnt-3a or BMP-4). Cells are incubated at 37°C, 95% humidity, 5% CO₂ for 72 hours. Medium is

-19-

removed, cells are washed with 200 μ L phosphate-buffered saline (“PBS”), and the PBS is removed. Cells are freeze-thawed 3 times. 100 μ L One-step pNPP substrate (Thermo Scientific catalogue #37621) is added per well, and the plate is incubated at room temperature. Absorbance is read at 405 nm. To determine the concentration of DKK-1 required to inhibit differentiation, Dkk-1 molecules from various species are titrated to identify the minimal concentration required to fully inhibit AP induction.

The minimal concentration of DKK-1 from each species which fully inhibits AP induction is as follows: human DKK-1=38 nM, cynomolgus DKK-1=11.4 nM, rat DKK-1=5.8 nM, and rabbit DKK-1= 25.0 nM.

Having determined the concentration of DKK-1 which fully inhibits AP induction, increasing concentrations of an anti-DKK-1 antibody are pre-incubated in assay medium with an inhibitory concentration of Dkk-1 for 30 minutes at room temperature. AP induction is determined as described above. Results are reported as an EC50 (nM $\pm$ standard error).

Antibody II blocks Dkk-1-mediated inhibition of C2C12 AP. For the DKK-1 of various species, the EC50's (given as nM $\pm$ standard error) are as follows: human = 9.8 $\pm$ 0.41, cynomolgus = 6.4 $\pm$ 0.25, rat= 2.9 $\pm$ 0.25, and rabbit = 6.0 $\pm$ 0.32.

Example 4: Cortical defect (CD) in vivo assay

Six month old female Sprague-Dawley rats are ovariectomized and allowed to lose bone for two months. 2 mm diameter defects are introduced into the left and right femurs with an electric drill with a 2 mm dental bit. This hole extends through both the anterior and posterior cortices. Healing of bone is monitored longitudinally by assessing bone mass density (“BMD”) through the use of quantitative computed tomography (“qCT”) for 35 days after surgery. At the end of the experiment, animals are sacrificed and whole femora are subjected to loaded-to-failure determinations to ascertain biomechanical strength of the whole diaphysis. Antibodies are administered subcutaneously at doses and intervals as indicated.

Antibody II is dosed as follows: 5 mg/kg once every two weeks starting one day after surgery (Group 1), 1 mg/kg (Group 2), 5 mg/kg (Group 3), or 15 mg/kg (Group 4) is administered once every two weeks starting nine days after surgery. BMD is assessed by qCT at day 35. Group 1 showed a statistically significant increase in BMD at both the

-20-

anterior and posterior cortices. Group 4 showed a statistically significant increase in BMD at both cortices, although Groups 2 and 3 showed a non-significant increase in BMD.

5 **Example 5: Cancer in vivo efficacy assay**

Mice (female C.B-17 mice, Fox Chase severe combined immunodeficient model # CB17SC-M) are acclimated for one week in an animal facility prior to experiment initiation. After acclimation, mice are randomized into groups of 10 per treatment. Cultured human A549 non-small cell lung carcinoma cells are implanted subcutaneously in the rear flank of the mice and tumor are allowed to reach a mean tumor volume ~ 100 mm³. Antibody II (1 mg/kg and 5 mg/kg), control IgG antibody (1 mg/kg and 5 mg/kg), or vehicle (citrate buffered saline supplemented with 0.02% Tween 80) is administered via subcutaneous injection. Animals receive 2 treatments separated by 7 days.

The tumors are measured 2 times per week by electronic calipers to plot growth curves. Animals are also monitored twice a week for fluctuations in body weight and signs of toxicity. Tumor volume measurements shown in table 3 are taken on day 29.

As shown in Table 2, treatment groups receiving Antibody II, demonstrated significant growth inhibition of human A549 non-small cell lung xenografts in vivo.

20 **Table 2: Efficacy of Antibody II in A549 human non-small cell lung carcinoma xenograft model**

Treatment Group	Tumor Volume ± Standard Error (mm ³)	p-Value (relative to vehicle control group)
Citrate vehicle	402 ± 36	-
IgG control (1 mg/kg)	372 ± 45	-
IgG control (5 mg/kg)	492 ± 72	-
Antibody II (1 mg/kg)	279 ± 32	0.01 – 0.05
Antibody II (5 mg/kg)	202 ± 21	< 0.001

Example 6: Angiogenic re-normalization in vivo xenograft assay

25 To understand the mechanism of the anti-tumor efficacy, high content imaging analysis is carried out on A549 tumors treated with Antibody II or IgG control. Several

-21-

phenotypic-based markers are analyzed both quantitatively and qualitatively to assess the cancer-relevant biological processes of angiogenesis (CD31 and smooth muscle actin, SMA), hypoxia induction (Glucose transporter 1, GLUT1), cell proliferation (Ki67), and apoptosis (Terminal UDP Nick-End Labeling, TUNEL).

5 Female C.B-17 (Fox Chase SCID) model # CB17SC-M mice age 7 to 8 weeks old are acclimated for one week and allowed to feed *ad libitum* on a normal low fat (4.5%) diet, which is continued for the duration of the study.

A549 cells from ATCC origin are grown and divided in F-12 Kaighn's media (Invitrogen #21127) supplemented with 10% FBS (Invitrogen #0, and 100x dilutions of
10 sodium pyruvate, non-essential amino acids and pen-strep (Invitrogen #11360, #11140 and #15140 respectively). They are detached and prepared at a final concentration of 50×10^6 cells/ml in PBS at passage 19 with 95% viability.

5×10^6 A549 human lung carcinoma cells are injected subcutaneously in the flank of subject mice in a 1:1 mixture of PBS and Matrigel (Becton Dickinson, Bedford, MA).
15 Tumor and body weight measurements are performed twice weekly. Prior to treatment, mice are randomized based on tumor size using a randomization algorithm.

Starting when tumors reached 200 mm^3 , the randomized mice are separated into 2 groups of 10 animals and dosed subcutaneously on day 1 and again on day 8 with 5 mg/kg of either Antibody II or the IgG4 control. The study is terminated 10 days after
20 administration of the first dose of antibody.

Antibody II is prepared in Citrate Buffered Saline (CBS) (10 mM citrate pH6, 150 mM NaCl and 0.2% polysorbate). IgG4 control is provided at 6.0 mg/ml in Phosphate Buffered Saline (PBS).

Xenograft tumors are excised from mice after 17 days of dosing and placed into
25 Zinc-Tris fixative (BD Pharmingen). Fixed tumors are processed, blocked in paraffin, and sectioned as $3 \mu\text{M}$ slices onto standard microscope slides. Slides are baked at 60°F for 1 hour and then deparaffinized in xylene (4 treatments, 10 minutes each). Slides are rehydrated through a series of ethanol/water immersions with final washes in Tris-buffered saline/Tween (TBST). Slides are then blocked with Protein Block (DAKO) for
30 30 minutes. For the Tumor Health Panel, slides are stained with a combination of Hoechst 33324 (Invitrogen), rat anti-human CD31 (Pharmingen)/anti-rat Alexa-488 (Invitrogen), rabbit anti-Ki67 (NeoMarkers)/anti-rabbit Alexa 647 (Invitrogen), and

-22-

TUNEL-TMR red (diluted 1:5 in TUNEL dilution buffer; Roche). For the Angiogenesis Panel, slides are stained with a combination of Hoechst 33324 (Invitrogen), rat anti-human CD31 (PharMingen)/anti-rat Alexa-488 (Invitrogen), rabbit anti-GLUT1 (Chemicon)/anti-rabbit Alexa 647 (Invitrogen), and mouse anti-Smooth Muscle Actin/Cy3 (Sigma). Slides are imaged using an iCys Laser Scanning Cytometer (CompuCyte) and a Marianas Digital Imaging Workstation configured with a Zeiss Axiovert 200M inverted fluorescence microscope (Intelligent Imaging Innovations). Quantitative data comparisons of treatment groups are performed using the Dunnet's analysis in JMP statistics software (SAS).

As shown in Table 3, A549 xenografts from control IgG-treated animals are modestly vascularized, have moderate levels of myofibroblasts and many focalized areas of hypoxia. Control IgG-treated tumors have an extended network of vessels consisting of both neoangiogenic vascular sprouts and mature vessels that are poorly covered by pericytes. Control IgG-treated tumors have hypoxic areas (marked by GLUT1) that are clearly demarcated zones some distance from perfused vessels and necrotic areas that are even further from vessels. Treatment with Antibody II results in decreased vessel area, decreased pericyte area, and decreased pericyte coverage of vessels. However, this treatment did not result in a significant difference in tumor hypoxia. Qualitatively, the Antibody II-treated tumor vasculature appears to consist of smaller, less-networked vessels and with less pericyte coverage compared with the control IgG-treated group.

As shown in Table 3, IgG-treated tumors have proliferating tumor cells evenly distributed throughout, but also frequently display one or more large areas of necrosis that are avascular. Treatment with Antibody II results in no change in apoptosis and only a slight, non-significant decrease in total proliferation area. However, there is a profound decrease in the percentage of area of high-intensity Ki67 cells in the Antibody II-treated tumors, which could indicate a decreased amount of cells in the G2 cell cycle phase.

-23-

Table 3: Antibody II in angiogenic re-normalization in vivo xenograft assay

Phenotypic Panel	Biological Parameter	Control IgG Value : Antibody II Treatment Value	Statistical Significance (Dunnet's p-value)
Tumor Angiogenesis Panel	% Total Vessel Area	10.26 : 7.88	0.001
Tumor Angiogenesis Panel	% Functional Vessel Area	9.84 : 7.59	0.0009
Tumor Angiogenesis Panel	% Non-Functional Vessel Area	0.42 : 0.30	0.1341
Tumor Angiogenesis Panel	% Pericyte Covered Vessels	42.44 : 30.88	0.0234
Tumor Angiogenesis Panel	% Tumor Hypoxic Area	14.90 : 11.77	0.3615
Tumor Proliferation Panel	% Tumor Proliferation Area	12.16 : 9.68	0.1739
Tumor Proliferation Panel	% High Ki67 Area	0.66 : 0.19	0.0012
Tumor Proliferation Panel	% Cycling Tumor Cells with High Ki67	5.24 : 1.68	<0.0001
Tumor Apoptosis Panel	% Tumor Apoptosis Area	8.63 : 8.24	0.7466
% Total Vessel Area – Percentage of tumor tissue area covered by all vessels regardless of their functional status.			
% Functional Vessel Area – Percentage of tumor tissue area covered by vessels in non-hypoxic regions.			
% Non-Functional Vessel Area – Percentage of tumor tissue area covered by vessels in hypoxic regions.			
% Pericyte Covered Vessels – Percentage of all tumor vessels that are associated with smooth muscle actin (SMA)-expressing cells.			
% Tumor Hypoxic Area – Percentage of tumor tissue area covered by cells			

-24-

expressing GLUT1, a surrogate marker for hypoxia.
% Tumor Proliferation Area – Percentage of tumor tissue area that is positive for Ki67, a nuclear protein routinely used as a marker of actively proliferating cells.
% High Ki67 Area - Percentage of tumor tissue area that stains intensely for Ki67. Cells expressing high levels of Ki67 are in later phases of cell cycle than those that express lower levels of Ki67.
% Cycling Tumor cells with High Ki67 - Percentage of all Ki67 positive cells that are designated as having a high level of Ki67 expression. Cells expressing high levels of Ki67 are in later phases of cell cycle than those that express lower levels of Ki67.
% Tumor Apoptosis Area – Percentage of tumor tissue area with high TUNEL staining. TUNEL is a routinely used method to detect double-stranded DNA breakages which is indicative of terminal apoptosis.

Example 7: Bone in vivo efficacy assay

To evaluate the ability of Antibody V (Light chain SEQ ID NO:34 and Heavy chain SEQ ID NO:35) accelerating the peri-implant bone formation and regenerating bone tissue, four months old male Sprague-Dawley rats (Harlan Sprague Dawley Inc) weighting around 425gram are utilized. Rats are surgically implanted with titanium screw (2 mm x 4mm) into the both legs of the media lateral side right above the tibial – fibular junction. Rats then are randomly divided into 2 groups according the body weight and receive either Antibody V 10mg/kg or IgG control 10mg/kg subcutaneously injection once weekly starting the same day of the surgery for 21 days. Quantitative computed tomography (Aloka LaTheta LTC-100 model CT scanner) is used to *ex vivo* scan and quantify the newly formed bone with a 60- μ m voxel size. Volume of interest (VOI) is defined as 28 slices at 0.1mm interval over the previous implant site. Group differences are assessed with JMP version 5.1. software (Cary, North Carolina), comparison against IgG-control using Dunnett's Method with a significance level of $P < 0.05$. Qualitatively evaluation by *ex vivo* faxitron x-ray images indicates that Antibody V treated rats have more new bone or callus around the implant. Quantitative CT analyses reveal a statistically significant increase cortical peri-implant bone mineral content (14%), new bone area (16%), cortical thickness (7%) and bone marrow cancellous peri-implant new bone mineral content (18%), and bone area (16%) in Antibody V treated rats when

-25-

compared to IgG control. The data demonstrate that Antibody V stimulates new bone formation and accelerate regenerating bone tissue in titanium implanted rats.

Table 4: Micro-CT analyses of Peri-implant New Bone Formation

Group	n	Bone Marrow Peri-implant Analyses		Cortical Peri-implant Analyses		
		Bone mineral Content (mg)	Bone Area (cm ²)	Bone mineral Content (mg)	Bone Area (cm ²)	Cortical thickness (cm)
IgG control	10	0.84 ±0.04	0.034 ±0.001	6.70 ±0.07	0.064 ±0.001	0.054 ±0.001
Antibody V	10	1.00 ±0.04*	0.039 ±0.002*	7.61 ±0.06*	0.074 ±0.001*	0.057 ±0.001*

Data are presented as Mean ± SE. *, p<0.05, vs IgG control, JMP Dunnett's test.

-26-

SEQ ID Listing**Heavy Chain CDRs**

5 SEQ ID NO:1 GFTFSSYTMS
SEQ ID NO:2 TISGGGFGTYYPDSVKG
SEQ ID NO:3 PGYHNYFDI
SEQ ID NO:4 PGYNNYFDI

10

Light Chain CDRs

SEQ ID NO:5 HASDSISNSLH
SEQ ID NO:6 YGRQSIQ
15 SEQ ID NO:7 QQSESWPLH
SEQ ID NO:8 YARQSIQ
SEQ ID NO:9 QQSASWPLH
SEQ ID NO:10 YARQSEQ

20

Heavy Chain Variable Regions

SEQ ID NO:11
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGG
25 GFGTYYPDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARPGYHNYFDI
WGQGTTVTVSS

SEQ ID NO:12
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGG
30 GFGTYYPDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARPGYNNYFDI
WGQGTTVTVSS

Light Chain Variable Regions

35

SEQ ID NO:13
EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYGRQSIQG
IPARFSGSGSGTDFTLTISSELPEDFAVYYCQQSESWPLHFGGGTKVEIK

40

SEQ ID NO:14
EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQG
IPARFSGSGSGTDFTLTISSELPEDFAVYYCQQSESWPLHFGGGTKVEIK

45

SEQ ID NO:15
EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYGRQSIQG
IPARFSGSGSGTDFTLTISSELPEDFAVYYCQQSASWPLHFGGGTKVEIK

-27-

SEQ ID NO:16

EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSEQ
GIPARFSGSGSGTDFTLTISSELEPEDFAVYYCQQSASWPLHFGGGGTKVEIK

5

Complete Heavy Chains

SEQ ID NO:17

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGG
10 GFGTYYPDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARPGYHNYYFDI
WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDPHKPSNTKVDKRVE
SKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL
15 LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHENHNT
QKSLSSSLG

SEQ ID NO:18

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGG
20 GFGTYYPDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARPGYNYYFDI
WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDPHKPSNTKVDKRVE
SKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQF
25 NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL
LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHENHNT
QKSLSSSLG

30

Complete Light Chains

SEQ ID NO:19

EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYGRQSIQG
35 IPARFSGSGSGTDFTLTISSELEPEDFAVYYCQQSESWSPLHFGGGGTKVEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO:20

EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQG
40 IPARFSGSGSGTDFTLTISSELEPEDFAVYYCQQSESWSPLHFGGGGTKVEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

45

SEQ ID NO:21

EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYGRQSIQG
IPARFSGSGSGTDFTLTISSELEPEDFAVYYCQQSASWPLHFGGGGTKVEIKRTVAAP

-28-

SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO:22

5 EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSEQ
GIPARFSGSGSGTDFTLTISSELPEDFAVYYCQQSASWPLHFGGGTKVEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

10

Nucleotide Sequences - Heavy Chain Variable Regions

SEQ ID NO:23

15 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGGTCCC
TGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATAACCATGTCTT
GGGTCCGCCAGGCTCCAGGGAAGGGGGCTGGAGTGGGTGGCCACCATTTCCGG
TGGTGGTTTCGGCACATACTATCCCGACAGTGTGAAGGGTTCGATTCACCATCT
CCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGC
CGAGGACACGGCTGTGTATTACTGTGCGAGACCTGGATATCACAACCTACTACT
20 TTGACATCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAA
GGGCCCATCGGTCTTCCCGCTAGCGCCCTGCTCCAGGAGCACCTCCGAGAGC
ACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG
TGTCGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAG
25 CAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCT
GCCCAGCACCTGAGGCCGCCGGGGGACCATCAGTCTTCCTGTTCCCCCCTAAA
ACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTACAGTGCGTGGTG
GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATG
30 GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCG
AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACA
CCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTGAGCCTGACCTG
35 CCTGGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGGAAAGCAAT
GGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGA
GGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACA
CACAGAAGAGCCTCTCCCTGTCTCTGGGT

40

SEQ ID NO:24

45 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGGTCCC
TGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATAACCATGTCTT
GGGTCCGCCAGGCTCCAGGGAAGGGGGCTGGAGTGGGTGGCCACCATTTCCGG
TGGTGGTTTCGGCACATACTATCCCGACAGTGTGAAGGGTTCGATTCACCATCT
CCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGC
CGAGGACACGGCTGTGTATTACTGTGCGAGACCTGGATATAATAACTACTACT

-29-

TTGACATCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAA
 GGGCCCATCGGTCTTCCCGCTAGCGCCCTGCTCCAGGAGCACCTCCGAGAGC
 ACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG
 TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
 5 CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAG
 CAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAAC
 ACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCACCCCT
 GCCCAGCACCTGAGGCGCCGGGGGACCATCAGTCTTCCTGTTCCCCCCTAAA
 ACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTACAGTGCGTGGTG
 10 GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATG
 GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACA
 GCACGTACCGTGTGGTCAGCGTCCTACCGTCTCCTGCACCAGGACTGGCTGAAC
 GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCTCCATCG
 AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACA
 15 CCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTACGCCTGACCTG
 CCTGGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGGAAAGCAAT
 GGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
 GCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGA
 GGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACA
 20 CACAGAAGAGCCTCTCCCTGTCTCTGGGT

Nucleotide Sequences - Light Chain Variable Regions

25 SEQ ID NO:25
 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAG
 AGCCACCCTCTCCTGCCACGCCAGCGACAGTATTAGCAACAGCCTACACTGGT
 ACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATTATGGCAGACA
 GTCCATCCAGGGCATCCCAGCCAGGTTTCAAGTGGCAGTGGGTCTGGGACAGAC
 30 TTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTG
 TCAACAGAGTGAGAGCTGGCCGCTCCACTTCGGCGGAGGGACCAAGGTGGAG
 ATCAAACGAACCTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
 GCAGTTGAAATCTGGAACCTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
 CCAGAGAGGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
 35 CTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
 AGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
 ACAGGGGAGAGTGC

40 SEQ ID NO:26
 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAG
 AGCCACCCTCTCCTGCCACGCCAGCGACAGTATTAGCAACAGCCTACACTGGT
 ACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATTATGCTAGACA
 GTCCATCCAGGGCATCCCAGCCAGGTTTCAAGTGGCAGTGGGTCTGGGACAGAC
 45 TTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTG
 TCAACAGAGTGAGAGCTGGCCGCTCCACTTCGGCGGAGGGACCAAGGTGGAG
 ATCAAACGAACCTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA

-30-

GCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
5 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
ACAGGGGAGAGTGC

SEQ ID NO:27

GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAG
10 AGCCACCCTCTCCTGCCACGCCAGCGACAGTATTAGCAACAGCCTACACTGGT
ACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATTATGGCAGACA
GTCCATCCAGGGGCATCCCAGCCAGGTTTCAAGTGGCAGTGGGTCTGGGACAGAC
TTCCTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTG
TCAACAGAGTGCCAGCTGGCCGCTCCACTTCGGCGGAGGGACCAAGGTGGAG
15 ATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
GCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
20 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
ACAGGGGAGAGTGC

SEQ ID NO:28

GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAG
25 AGCCACCCTCTCCTGCCACGCCAGCGACAGTATTAGCAACAGCCTACACTGGT
ACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATTATGCTAGACA
GTCCGAGCAGGGGCATCCCAGCCAGGTTTCAAGTGGCAGTGGGTCTGGGACAGAC
TTCCTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTG
TCAACAGAGTGCCAGCTGGCCGCTCCACTTCGGCGGAGGGACCAAGGTGGAG
30 ATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
GCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
35 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
ACAGGGGAGAGTGC

Human DKK-1

40
SEQ ID NO:29
TLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQPYP
EDEECGTDEYCASPTRGGDAGVQICLACRKRRCMRHAMCCPGNYCKNGICV
SSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLR
45 ASGLCCARHFWKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLS
CRIQKD
HHQASNSSLHTCQRH

-31-

Cynomolgus DKK-1

SEQ ID NO:30

5 TLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQPYP
EDEECGTDEYCASPTRGGDAGVQICLACRKRRKRCMRHAMCCPGNYCKNGICV
SSDQNNFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHSGKGQEGSVCLRSSDC
ATGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLScriQKD
HHQASNSSLHTCQR
10

Rat DKK-1

SEQ ID NO:31

15 TLNSVLINSNAIKNLPPPLGGAGGQPGSAVSVAPGVLYEGGNKYQTLDNYPYP
AEDEECGTDEYCSSPSRGAAGVGGVQICLACRKRRKRCMRHAMCCPGNYCKNG
ICMPSDHSHLPRGEIEEGIIENLGNDHGAGDGYPRRTTLTSKIYHTKGQEGSVCLR
SSDCATGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLAC
RIQKDHHQTSNSSLHTCQRHAFIDYKDDDDKHV
20

Rabbit DKK-1

SEQ ID NO:32

25 TLNSVLVNSNAIKNLPPPLGGANGHPGSAVSATPGILYEGGNKYLPLDNYPYP
TEDEECGTDEYCASPARGGGAGVQICLACRKRRKRCMRHAMCCPGNYCKNGIC
MPSDHNHFHRGEIEETIVESFGNDHSTSDGYSRRTTLSSKMYHAKGQEGSVCLRS
SDCATGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGDGLSCR
LQNDQHEASNSSLHTCQR
30

Mouse DKK-1

SEQ ID NO:33

35 TLNSVLINSNAIKNLPPPLGGAGGQPGSAVSVAPGVLYEGGNKYQTLDNYPYP
AEDEECGSDEYCSSPSRGAAGVGGVQICLACRKRRKRCMTHAMCCPGNYCKNG
ICMPSDHSHFPRGEIEESIIENLGNDHNAAAGDGYPRRTTLTSKIYHTKGQEGSV
LRSSDCAAGLCCARHFWSKICKPVLKEGQVCTKHKRKGSHGLEIFQRCYCGEGL
ACRIQKDHHQASNSSLHTCQRH
40

Antibody V - Complete Light Chain

SEQ ID NO:34

45 DILLTQSPATLSVTPGDSVSLSCRASDSISGSLHWYQQKSHESPRLLIKYASQSIGI
PSRFSGSGSGTDFTLINSVETEDFGMYFCQQSNSWPLNFGAGTKLELKRADAAP

-32-

TVSIFPPSTEQLATGGASVVCLMNNFYPRDISVKWKIDGTERRDGVLDSDVTDQDS
KDSTYSMSSTLSLSKADYESHNLTYTCEVVHKTSSSPVVKSFNRECE

5 Antibody V - Complete Heavy Chain

SEQ ID NO:35

EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISGG
GGNTYYPDSVKGRFTISRDNKNTLYLQLSSLRSEDALYYCARPGYNNYYFDY
10 WGQGTTLTVSSAKTTPPSVYPLAPGTALKSNSMVTLGCLVKGYFPEPVTVTWNS
GALSSGVHTFPAVLQSGLYTLTSSVTVPSSTWPSQTVTCNVAHPASSTKVDKKIV
PRNCGGDCKPCICTGSEVSSVFIFPPKPKDVLITLTTPKVTCTVVDISQDDPEVHFS
WFVDDVEVHTAQTTPPEEQFNSTFRSVSELPILHQDWLNGRTFRCKVTSAAFPSPI
EKTISKPEGRTQVPHVYTMSPTEEMTQNEVSITCMVKGFYPPDIYVEWQMNGQ
15 PQENYKNTPTMDTDGSYFLYSKLNVKKEKWQQGNTFTCSVLHEGLHNHHTK
SLSHSPGK

Antibody V - Light Chain Variable Region

20

SEQ ID NO:36

DILLTQSPATLSVTPGDSVSLSCRASDSISGSLHWYQQKSHESPRLLIKYASQSIGI
PSRFGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPLNFGAGTKLELK

25

Antibody V - Heavy Chain Variable Region

SEQ ID NO:37

EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISGG
30 GGNTYYPDSVKGRFTISRDNKNTLYLQLSSLRSEDALYYCARPGYNNYYFDY
WGQGTTLTVSS

Antibody V - Heavy Chain CDRs

35

SEQ ID NO:38 TISGGGGNTYYPDSVKG
SEQ ID NO:39 PGYNNYYFDY

40 Antibody V - Light Chain CDRs

SEQ ID NO:40 RASDSISGSLH
SEQ ID NO:41 YASQSIGI
SEQ ID NO:42 QQSNSWPLN

-33-

Consensus Heavy Chain CDRs

5 SEQ ID NO:43 TISGGGX₁X₂TYYPDSVKG
X₁ is F, G
X₂ is G, N

10 SEQ ID NO:44 PGYX₃NYFYDI
X₃ is H, N

15 SEQ ID NO:45 PGYX₄NYFYDX₅
X₄ is H, N
X₅ is I, Y

Consensus Light Chain CDRs

20 SEQ ID NO:46 X₆ASDSISX₇SLH
X₆ is H, R
X₇ is N, G

25 SEQ ID NO:47 YX₈RQSX₉Q
X₈ is G, A
X₉ is I, E

30 SEQ ID NO:48 YX₁₀X₁₁QSX₁₂X₁₃
X₁₀ is G, A
X₁₁ is R, S
X₁₂ is I, E
X₁₃ is Q, S

35 SEQ ID NO:49 QQSX₁₄SWPLH
X₁₄ is E, A

40 SEQ ID NO:50 QQSX₁₅SWPLX₁₆
X₁₅ is E, A, N
X₁₆ is H, N

-34-

Consensus Heavy Chain Variable Region

SEQ ID NO:51

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGG

GFGTYYPDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARPGYX₁₇NYF

5 DI WGQGTTVTVSS

X₁₇ is H, N**Consensus Light Chain Variable Region**

10 SEQ ID NO:52

EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYX₁₈RQSX₁₉QGIPARFSGSGSGTDFTLTSSLEPEDFAVYYC QQSX₂₀SWPLHFGGGTKVEIKX₁₈ is G, AX₁₉ is I, E15 X₂₀ is E, A

CLAIMS:

1. A human engineered DKK-1 antibody or antigen-binding fragment thereof, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 52 and the HCVR comprises the amino acid sequence of SEQ ID NO: 51.
2. The human engineered DKK-1 antibody or antigen-binding fragment of claim 1, wherein the LCVR and HCVR comprise amino acid sequences selected from the group consisting of:
- (i) a LCVR comprising the amino acid sequence of SEQ ID NO: 13 and a HCVR comprising the amino acid sequence of SEQ ID NO: 11;
 - (ii) a LCVR comprising the amino acid sequence of SEQ ID NO: 14 and a HCVR comprising the amino acid sequence of SEQ ID NO: 12;
 - (iii) a LCVR comprising the amino acid sequence of SEQ ID NO: 15 and a HCVR comprising the amino acid sequence of SEQ ID NO: 11; and
 - (iv) a LCVR comprising the amino acid sequence of SEQ ID NO: 16 and a HCVR comprising the amino acid sequence of SEQ ID NO: 11.
3. The human engineered DKK-1 antibody or antigen-binding fragment of Claim 2, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 14 and the HCVR comprises the amino acid sequence of SEQ ID NO: 12.
4. The human engineered DKK-1 antibody or antigen-binding fragment of claim 1, wherein the human engineered DKK-1 antibody comprises a heavy chain and a light chain amino acid sequence selected from the group consisting of
- a. a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and light chain comprising the amino acid sequence of SEQ ID NO: 19,
 - b. a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20,

-36-

- c. a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a light chain comprising the amino acid sequence of SEQ ID NO: 21, and
- d. a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

5

5. The human engineered DKK-1 antibody or antigen-binding fragment of claim 4, comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO: 20, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO: 18.

10

6. A pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof of any one of Claims 1 to 5, and a pharmaceutically acceptable carrier, diluent, or excipient.

15

7. A pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof of any one of Claims 1 to 5 together with a pharmaceutically acceptable carrier, diluent, or excipient and optionally other therapeutic ingredients.

20

8. A human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for use in therapy.

9. A human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for use in the treatment for bone healing.

25

10. A human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for use in the treatment of cancer.

30

11. A human engineered DKK-1 antibody or antigen-binding fragment thereof, of Claim 10 for use in the treatment of cancer, wherein the cancer is selected from the group consisting of multiple myeloma, breast cancer, and non-small cell lung cancer.

-37-

12. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for treatment for bone healing.

5 13. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for the treatment of cancer.

14. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, according to Claim 13, wherein the cancer is selected from the group consisting of multiple myeloma, breast cancer, and non-small cell lung cancer.

10 15. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for manufacture of a medicament for treatment for bone healing.

15 16. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, of any one of Claims 1 to 5 for manufacture of a medicament for the treatment of cancer.

20 17. Use of a human engineered DKK-1 antibody or antigen-binding fragment thereof, according to Claim 16, wherein the cancer is selected from the group consisting of multiple myeloma, breast cancer, and non-small cell lung cancer.